daunorubicin has been researched along with decitabine in 14 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (14.29) | 18.2507 |
| 2000's | 3 (21.43) | 29.6817 |
| 2010's | 7 (50.00) | 24.3611 |
| 2020's | 2 (14.29) | 2.80 |
| Authors | Studies |
|---|---|
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Di Leone, L; Fernandes, MS; Gerhardt, LM; Kalakun, L; Loitzembauer, B; Moschen, M; Schaan, MD; Schwartsmann, G | 1 |
| deSilva, M; El-Osta, A; Hu, XF; Kantharidis, P; Nadalin, G; Parkin, JD; Slater, A; Wall, DM; Zalcberg, JR | 1 |
| Barge, RM; Honders, MW; Spoelder, HE; Veuger, MJ; Willemze, R | 1 |
| Bouabdallah, K; Daskalakis, M; Johansson, B; Kunzmann, R; Lübbert, M; Mauritzson, N; Müller-Berndorff, H; Onida, F; Schmitt-Gräff, A | 1 |
| Karp, J | 1 |
| Czemerska, M; Grzybowska-Izydorczyk, O; Pluta, A; Robak, T; Szmigielska-Kapłon, A; Wierzbowska, A; Wolska, A | 1 |
| Bose, JR; Brenet, F; Curcio, TJ; Feldman, EJ; Gergis, US; Ippoliti, CM; Mayer, SA; Moh, M; Morawa, E; Ritchie, EK; Roboz, GJ; Scandura, JM; Villegas, L | 1 |
| Hou, CF; Luo, J; Ma, LM | 1 |
| Alvaro, F; Arceci, RJ; Arndt, C; Barnette, P; Boklan, J; Carpten, J; Cooper, T; Farrar, JE; Gooden, GC; Gore, L; Lee, D; Legendre, C; Liang, WS; Macy, ME; Martin, L; Meshinchi, S; Narendran, A; Pollard, J; Salhia, B; Triche, TJ; Wai, D | 1 |
| Choi, EJ; Jeon, M; Kang, YA; Lee, JH; Lee, KH; Lee, YS; Park, HS; Seol, M; Woo, JM | 1 |
| Baker, SD; Behbehani, G; Bhatnagar, B; Blachly, J; Blum, W; Buelow, DR; Byrd, JC; Garzon, R; Jeon, JY; Klisovic, RB; Mims, AS; Phelps, M; Vasu, S; Walker, AR; Zhao, Q | 1 |
| Huang, L; Hui, Y; Li, Y; Mao, X; Shang, Z; Wang, Y; Wang, Z; Wei, J; Xiao, M; Zhang, D; Zheng, L | 1 |
2 review(s) available for daunorubicin and decitabine
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Novel and emerging drugs for acute myeloid leukemia: pharmacology and therapeutic activity.
Topics: Adenine Nucleotides; Animals; Arabinonucleosides; Azacitidine; Benzamides; Clofarabine; Cytarabine; Cytosine; Daunorubicin; Decitabine; Dioxolanes; Farnesyltranstransferase; Histone Deacetylase Inhibitors; Humans; Hydrazines; Imatinib Mesylate; Leukemia, Myeloid, Acute; Liposomes; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Sulfonamides; TOR Serine-Threonine Kinases; Valproic Acid; Vascular Endothelial Growth Factor Receptor-1 | 2011 |
4 trial(s) available for daunorubicin and decitabine
| Article | Year |
|---|---|
Decitabine (5-Aza-2'-deoxycytidine; DAC) plus daunorubicin as a first line treatment in patients with acute myeloid leukemia: preliminary observations.
Topics: Adult; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Bone Marrow; Daunorubicin; Decitabine; Drug Administration Schedule; Female; Humans; Immunophenotyping; Infusions, Intravenous; Karyotyping; Leukemia, Myeloid, Acute; Male; Middle Aged | 1997 |
Phase 1 study of epigenetic priming with decitabine prior to standard induction chemotherapy for patients with AML.
Topics: Acute Disease; Adult; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Cytarabine; Daunorubicin; Decitabine; Diarrhea; DNA Methylation; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fever; Humans; Infections; Kaplan-Meier Estimate; Leukemia, Myeloid; Male; Middle Aged; Nausea; Neutropenia; Treatment Outcome; Young Adult | 2011 |
A multicenter, randomized study of decitabine as epigenetic priming with induction chemotherapy in children with AML.
Topics: Adolescent; Azacitidine; Child; Child, Preschool; Cytarabine; Daunorubicin; Decitabine; DNA Methylation; Epigenesis, Genetic; Etoposide; Female; Humans; Induction Chemotherapy; Infant; Leukemia, Myeloid, Acute; Male; Promoter Regions, Genetic; Treatment Outcome | 2017 |
Preclinical activity and a pilot phase I study of pacritinib, an oral JAK2/FLT3 inhibitor, and chemotherapy in FLT3-ITD-positive AML.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bridged-Ring Compounds; Cell Line, Tumor; Cell Survival; Cytarabine; Daunorubicin; Decitabine; Drug Resistance, Neoplasm; Female; fms-Like Tyrosine Kinase 3; Humans; Janus Kinase 2; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Male; Middle Aged; Mutation; Pilot Projects; Protein Kinase Inhibitors; Pyrimidines | 2020 |
8 other study(ies) available for daunorubicin and decitabine
| Article | Year |
|---|---|
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Altered methylation of the human MDR1 promoter is associated with acquired multidrug resistance.
Topics: Antimetabolites, Antineoplastic; ATP Binding Cassette Transporter, Subfamily B, Member 1; Azacitidine; Blotting, Southern; Daunorubicin; Decitabine; Dinucleoside Phosphates; DNA Methylation; Drug Resistance, Multiple; Epirubicin; Exons; Humans; Introns; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, T-Cell; Promoter Regions, Genetic; Restriction Mapping; Transcription, Genetic; Tumor Cells, Cultured; Verapamil | 1997 |
Inactivation of deoxycytidine kinase and overexpression of P-glycoprotein in AraC and daunorubicin double resistant leukemic cell lines.
Topics: 2-Chloroadenosine; Alternative Splicing; Animals; ATP Binding Cassette Transporter, Subfamily B, Member 1; Azacitidine; Biological Transport; Buthionine Sulfoximine; Calcium Channel Blockers; Cytarabine; Daunorubicin; Decitabine; Deoxyadenosines; Deoxycytidine Kinase; DNA Mutational Analysis; DNA, Neoplasm; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Glutathione; Humans; Idarubicin; Leukemia; Methotrexate; Neoplasm Proteins; Rats; Reverse Transcriptase Polymerase Chain Reaction; Tumor Cells, Cultured; Verapamil | 2003 |
Trisomy 19 as the sole chromosomal abnormality in proliferative chronic myelomonocytic leukemia.
Topics: Aged; Azacitidine; Chromosome Aberrations; Chromosomes, Human, Pair 19; Cytarabine; Cytogenetic Analysis; Daunorubicin; Decitabine; Dose-Response Relationship, Drug; Fatal Outcome; Female; Humans; Hydroxyurea; Leukemia, Myelomonocytic, Chronic; Male; Middle Aged; Myelodysplastic Syndromes; Phenotype; Steroids; Treatment Outcome | 2006 |
Future research directions for the treatment of AML.
Topics: Antineoplastic Agents; Azacitidine; Biomedical Research; Carbazoles; Carboplatin; Cytarabine; Daunorubicin; Decitabine; Enzyme Inhibitors; Etoposide; Flavonoids; Furans; Humans; Leukemia, Myeloid, Acute; Mitoxantrone; Piperidines; Quinolones; Staurosporine; Topotecan; Tretinoin | 2008 |
[Effect of proliferation inhibition and PTEN gene expression induced by decitabine combined with daunorubicin on HL-60 cell line].
Topics: Azacitidine; Cell Proliferation; Daunorubicin; Decitabine; HL-60 Cells; Humans; PTEN Phosphohydrolase | 2012 |
Decitabine Versus Intensive Chemotherapy for Elderly Patients With Newly Diagnosed Acute Myeloid Leukemia.
Topics: Age Factors; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Decitabine; Disease-Free Survival; DNA Methylation; Female; fms-Like Tyrosine Kinase 3; Follow-Up Studies; Gene Duplication; Humans; Idarubicin; Infusions, Intravenous; Leukemia, Myeloid, Acute; Male; Prognosis; Remission Induction; Retrospective Studies; Time Factors | 2019 |
Clinical efficacy of decitabine‑containing induction chemotherapy in de novo non‑elderly acute myeloid leukemia.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Decitabine; DNA Methylation; Female; Humans; Induction Chemotherapy; Leukemia, Myeloid, Acute; Male; Middle Aged; Mutation; Survival Analysis; Treatment Outcome; Young Adult | 2020 |